Trump's Policies Raise Concerns: Indian Pharmaceutical Exports Face High Tariffs, but Demand for Generic Drugs May Remain Strong

Following the successful election of Donald Trump as the 47th President of the United States, India's life sciences and pharmaceutical industries are watching closely to see how the new administration's "America First" policies will affect US trade dynamics, FDA regulations, and market access. Although many experts have foreseen the challenges and potential opportunities this policy could bring, they generally do not expect the FDA to make major regulatory changes to Indian companies. Prashant Khadayate, director of Life Sciences Consulting and research at GlobalData, stressed that while Indian pharmaceutical exports may face obstacles from high tariffs, demand for Indian generics is likely to remain strong as the US prioritizes affordable healthcare solutions. "Even in the context of protectionist policies, the focus on cost-effective healthcare should keep interest in high-quality generic drugs in India high," he noted.

India's medtech, telemedicine, and medical device industries, while growing rapidly, are likely to remain challenging to gain substantial traction in the US market. However, as U.S. companies seek new global partnerships, the anti-China stance could provide long-term opportunities for these industries. Indian CDMO companies are preparing to take advantage of these shifts by investing in advanced manufacturing technologies and expanding production capacity. For those in the US, potential incentives for domestic manufacturing could further enhance their competitiveness in the US market. Underlining the importance of global access to affordable medicines and healthcare security, Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain highlighted the key role of the US-India Affordable Medicines Partnership. Jain said: "India plays a key role in the US healthcare system by providing affordable, quality-assured medicines. This partnership will continue to grow, promoting a diverse and resilient supply chain for apis and advancing global health care security."

While Trump's potential policies could create new obstacles for Indian pharmaceutical exports, they also present an opportunity for Indian companies to strengthen their presence in the US market and support a more resilient and diversified global healthcare supply chain.